SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Global HIV Therapeutics in Major Developed Markets to 2019

[April 22, 2014]

Research and Markets: Global HIV Therapeutics in Major Developed Markets to 2019

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/tct7jd/hiv_therapeutics) has announced the addition of the "HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth" report to their offering.

Patent Protection Losses Will Hinder HIV Treatment Market Growth Within Seven Years

Thanks to patent expirations of several key therapies, the Human Immunodeficiency Virus (HIV) treatment market value will increase at a slow pace in the coming years, from $14.3 billion in 2012 to $16.3 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 1.9%.

According to the company's latest report, the first-line antiretroviral therapies Atripla and Truvada will lose patent protection during the forecast period, which will hurt their markets in Europe and Canada.

<> Angel Wong, report analyst, says: Despite such patent losses, a number of drugs will enter the HIV market by 2019. Among these new entrants, 572-Trii is expected to perform the strongest commercially and will compete with Atripla following its approval. However, these drugs will not offset the impact of generic erosion.


Currently, the HIV pipeline is strong and displays a high degree of novelty and diversity, according to the authors. The pipeline also consists of therapies that address the unmet needs of drug resistance and toxicity. These drugs are Nucleoside Reverse Transcriptase Inhibitor (NRTI) apricitabine, censavudine and elvucitabine, which deal with the issue of NRTI resistance.

Another candidate in the HIV pipeline, which is a new pro-drug of tenofovir, called tenofovir alafenamide, has also demonstrated a more favorable toxicity profile than its predecessor Viread.

Wong says: Despite the promising outlook, the HIV pipeline has suffered from high attrition rates in recent years, particularly with vaccines. None of these have been approved for the treatment of HIV. These failures reflect an urgent need for a more thorough understanding of immune response against HIV and more streamlined clinical trial designs, the analyst concludes.

This report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for HIV. Countries covered in this report include the US, France, Germany, Italy, Spain, the UK, Japan and Canada.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by a team of industry experts.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Marketed Products

4 Pipeline for HIV

5 Market Forecast to 2019

6 Deals and Strategic Consolidations

7 Appendix

For more information visit http://www.researchandmarkets.com/research/tct7jd/hiv_therapeutics


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.